磷酸西格列汀联合二甲双胍治疗初发2型糖尿病的临床观察

摘要

Objective To explore the effect of combination of sitagliptin and metformin in treatment of newly diagnosed type 2 diabetes.Methods Sixty cases of newly diagnosed type 2 diabetes were randomly divided into two groups:control group(30 cases)and treatment group(30 cases).The patients in control group were given metformin, those in treatment group(30 cases) received sitagliptin and metformin, the therapies lasted for 12 weeks.The changes in fasting blood-glucose (FBG),2 hours postprandial blood glucose (2 hPG) , glycated hemoglobin( HbA1c), body mass index)(BMI),fasting insulin(FINS) and HOMA-insulin resistance(HOMA-IR) were observed in two groups.Results After 12-week treatment, the levels of FBG, 2 hPG, HbA1c, BMI showed significant decease ( P < 0.01), but FINS was significantly increased( P <0.05).The curative effect of treatment group was better than that of control group, FBG(5.6±1.5) mmol/L vs (7.0±1.8) mmol/L(P <0.01);2 hPG(8.2±1.3) mmol/L vs (10.8±2.1) mmol/L (P<0.01);HbA1c(6.1±1.2)% vs (7.2±1.0)%( P <0.01);Fins(13.2±3.1) mU/L vs (11.5±2.3) mU/L( P <0.05).Conclusion Sitagliptin is an effective and safe new medicine in reducing plasma glucose.%目的 探讨西格列汀联合二甲双胍治疗初发2型糖尿病的疗效.方法 将60例初发2型糖尿病患者随机分为两组,对照组30例,单用二甲双胍治疗；治疗组30例,采用二甲双胍联合西格列汀治疗,观察12周,比较两组治疗前后空腹血糖(FBG),餐后2小时血糖(2 hPG),糖化血红蛋白(HbA1c)、体质量指数(BMI)、空腹胰岛素(FIns)、胰岛素抵抗指数(HOMA-IR)等指标的变化.结果 12周治疗后,两组FBG、2 hPG、HbA1c、BMI均明显减低(P＜0.01),FIns水平显著增加(P＜0.05)；治疗组疗效优于对照组,FBG(5.6±1.5) mmol/L vs (7.0±1.8)mmol/L(P＜0.01);2 hPG(8.2±1.3) mmol/L vs (10.8±2.1)mmol/L(P＜0.01); HbA1 c(6.1±1.2)％ vs (7.2±1.0)％(P ＜0.01)；FIns(13.2±3.1) mU/L vs (11.5±2.3) mU/L(P ＜0.05).结论 西格列汀是一种安全有效的新型降糖药物,且能更好的控制血糖.